ReShape Lifesciences (US:RSLS) Globenewswire·2025-07-21 18:10Core Viewpoint - ReShape Lifesciences' Board of Directors unanimously recommends a merger with Vyome Therapeutics and an asset sale to Biorad Medisys, believing these actions are in the best interests of the company and its shareholders [2][3]. Group 1: Merger and Asset Sale Details - The merger with Vyome Therapeutics aims to enhance the development of immune-inflammatory assets and leverage opportunities between the US and India [3]. - The asset sale involves transferring substantially all of ReShape's assets to Biorad Medisys, which is expected to facilitate the company's transformation [2][3]. - Independent proxy advisory firms ISS and Glass Lewis have recommended shareholders vote in favor of the merger and asset sale proposals [2]. Group 2: Shareholder Engagement - The company emphasizes the importance of shareholder votes, urging all shareholders to vote in favor of the proposals related to the issuance of common stock, asset sale, and board composition amendments [3][4]. - Shareholders who have not yet voted are encouraged to do so, and those who voted against the proposals are asked to reconsider [4][6]. Group 3: Company Backgrounds - ReShape Lifesciences specializes in weight loss and metabolic health solutions, offering products like the FDA-approved Lap-Band® System and the investigational Diabetes Bloc-Stim Neuromodulation™ system [11]. - Vyome Therapeutics focuses on developing therapies for immune-inflammatory conditions and plans to leverage its clinical-stage assets for growth [9]. - Biorad Medisys is a med-tech company with a focus on precision-engineered medical devices and has recently expanded its operations internationally [10].